A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
Open Access
- 11 September 1997
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 337 (11) , 725-733
- https://doi.org/10.1056/nejm199709113371101
Abstract
The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine with treatment with the two nucleosides alone in HIV-infected adults previously treated with zidovudine.Keywords
This publication has 35 references indexed in Scilit:
- Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panelPublished by American Medical Association (AMA) ,1997
- Host factors and the pathogenesis of HIV-induced diseaseNature, 1996
- Quantitative Image Analysis of HIV-1 Infection in Lymphoid TissueScience, 1996
- Association of Plasma Human Immunodeficiency Virus Type 1 RNA Level withRisk of Clinical Progression in Patients with Advanced InfectionThe Journal of Infectious Diseases, 1996
- Prognostic Value of Plasma Human Immunodeficiency Virus Type 1 (HIV-l) RNA Levels in Patients with Advanced HIV-l Disease and with Little or No Prior Zidovudine TherapyThe Journal of Infectious Diseases, 1996
- Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in PlasmaScience, 1996
- Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic MillimeterNew England Journal of Medicine, 1995
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Stopping rules and estimation problems in clinical trialsStatistics in Medicine, 1988